X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs MYLAN (US) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   MYLAN
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
MYLAN
Dec-18
SUN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7013,300-   
Low Rs4331,816-   
Sales per share (Unadj.) Rs110.41,518.3-  
Earnings per share (Unadj.) Rs11.041.2-  
Cash flow per share (Unadj.) Rs17.2325.5-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.81,642.5-  
Shares outstanding (eoy) m2,399.26514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.11.7 304.8%   
Avg P/E ratio x51.662.0 83.2%  
P/CF ratio (eoy) x32.97.9 418.7%  
Price / Book Value ratio x3.61.6 229.2%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,0211,316,044 103.3%   
No. of employees `00017.835.0 50.8%   
Total wages/salary Rs m53,6710-   
Avg. sales/employee Rs Th14,890.922,319.1 66.7%   
Avg. wages/employee Rs Th3,017.10-   
Avg. net profit/employee Rs Th1,480.6606.1 244.3%   
INCOME DATA
Net Sales Rs m264,895781,167 33.9%  
Other income Rs m8,3880-   
Total revenues Rs m273,282781,167 35.0%   
Gross profit Rs m56,081202,137 27.7%  
Depreciation Rs m14,998146,265 10.3%   
Interest Rs m5,17637,571 13.8%   
Profit before tax Rs m44,29518,300 242.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,452-2,911 -290.3%   
Profit after tax Rs m26,33821,212 124.2%  
Gross profit margin %21.225.9 81.8%  
Effective tax rate %19.1-15.9 -119.9%   
Net profit margin %9.92.7 366.2%  
BALANCE SHEET DATA
Current assets Rs m316,359436,203 72.5%   
Current liabilities Rs m198,643318,040 62.5%   
Net working cap to sales %44.415.1 293.8%  
Current ratio x1.61.4 116.1%  
Inventory Days Days9584 113.5%  
Debtors Days Days10893 115.4%  
Net fixed assets Rs m213,178151,534 140.7%   
Share capital Rs m2,399416 576.9%   
"Free" reserves Rs m378,6060-   
Net worth Rs m381,006845,080 45.1%   
Long term debt Rs m17,721912,113 1.9%   
Total assets Rs m643,0282,266,833 28.4%  
Interest coverage x9.61.5 642.7%   
Debt to equity ratio x01.1 4.3%  
Sales to assets ratio x0.40.3 119.5%   
Return on assets %4.92.6 189.0%  
Return on equity %6.92.5 275.4%  
Return on capital %10.03.2 315.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,6730-   
CASH FLOW
From Operations Rs m39,072162,327 24.1%  
From Investments Rs m-33,708-83,905 40.2%  
From Financial Activity Rs m-15,393-75,621 20.4%  
Net Cashflow Rs m-7,3591,345 -547.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 69.32 Rs / USD

Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: ALEMBIC LTD  TTK HEALTHCARE  PFIZER  WYETH LTD  CIPLA  



Today's Market

Sensex Ends Over 300 Points Higher; Energy and Metal Stocks Witness Buying(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views On News

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jun 25, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - PANACEA BIOTECH COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS